AI Stock Finder
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

KLRA vs STOK: stock comparison and AI forecast

Kailera Therapeutics, Inc. (KLRA) and Stoke Therapeutics, Inc. (STOK) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

KLRA Kailera Therapeutics, Inc.

Market Cap
$1.58B
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

STOK Stoke Therapeutics, Inc.

Price
$26.07 -21.7% · 6M
Market Cap
$1.68B
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

KLRA · STOK

Key facts

  • KLRA and STOK have similar market capitalizations ($1.58B and $1.68B).
  • STOK carries 0.15 times debt per unit of equity, against 0.05 times for KLRA.
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricKLRASTOK
Market Cap$1.58B$1.68B
P/B Ratio1.53x4.77x
EPS–$-3.78
Book Value/Share$7.95$5.46
Revenue/Share–$0.44
FCF/Share–$-3.34

Profitability & Margins

MetricKLRASTOK
ROE–-69.0%
ROA–-59.8%
ROIC–-72.0%
Operating Margin–-913.1%
Net Margin–-862.1%
EBT Margin–-910.6%
Tax Rate–0.0%

Financial Health

MetricKLRASTOK
Current Ratio21.84x7.24x
D/E Ratio0.05x0.15x
Financial Leverage1.05x1.15x
Interest Coverage–-3865.8x
Working Capital$878M$305M

Cash Flow

MetricKLRASTOK
Operating Cash Flow–-$210M
Free Cash Flow–-$216M
Capital Spending–-$5M
OCF Growth YoY–-498.0%
FCF Growth YoY–-511.9%
FCF/Sales–-764.7%
CapEx/Sales–19.2%

Operational Efficiency

MetricKLRASTOK
Asset Turnover–0.07x
Receivables Turnover–3.3x
Fixed Assets Turnover–3.4x
Days Sales Outstanding–111 days

Income Statement

MetricKLRASTOK
Total Revenue–$28M
Operating Income–-$258M
Net Income–-$243M
R&D Expense–$191M
SG&A Expense–$125M

Dividend & Shareholder Information

MetricKLRASTOK
Shares Outstanding130M65M
Net Income Growth–-699.5%
EPS Growth–-3007.7%
FAQ

KLRA vs STOK: stock comparison and AI forecast

Which is bigger, KLRA or STOK?

KLRA and STOK have similar market capitalizations ($1.58B and $1.68B).

Which one does Intratio's AI model rank higher, KLRA or STOK?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.